### **Company Update**

February 4, 2019

₹**1200** 

Rating matrix				
Rating	:	Hold		
Target	:	₹1300		
Target Period	:	12-18	months	
Potential Upside	:	8%		
What's changed?	)			
Target			Ur	changed
EPS FY19E		Changed	from ₹ 71.2	to ₹ 72.0
EPS FY20E		Changed	from ₹ 81.1	to₹81.2
Rating		Char	nged from Bu	y to Hold
Key financials				
₹ crore	FY17	FY18	FY19E	FY20E
Net Sales	297.5	328.2	381.7	414.0
EBITDA	87.3	98.2	122.4	133.3
Net Profit	53.4	56.8	72.1	81.3
EPS	51.8	55.1	72.0	81.2
Valuation summa	ry			
	FY17	FY18	FY19E	FY20E
P/E	23.2	21.8	16.7	14.8
Target P/E	25.1	23.6	18.0	16.0
EV / EBITDA	14.8	13.0	10.4	9.0
P/BV	3.7	3.2	2.9	2.5
RoNW	15.9	14.6	17.6	17.1
RoCE	15.3	15.5	19.0	22.4
ROIC	17.3	19.9	22.3	24.5

Stock data	
Stock Data	₹ crore
Market Capitalization	1237.2
Total Debt (FY18)	112.0
Cash and Cash Equivalent (FY18)	68.4
Enterprise Value	1280.8
52 week H/L	1418 / 901
Equity Capital	10.3
Face Value	₹10
MF Holding (%)	23.6
FII Holding (%)	0.4

#### **Research Analyst**

Chirag J Shah shah.chirag@icicisecurities.com Shashank Kanodia, CFA shashank.kanodia@icicisecurities.com

# **Oriental Carbon (ORICAR)**

# Firmly placed, next leg of capex on the anvil...

- Oriental Carbon & Chemicals (OCCL) reported a robust operational performance in Q3FY19 led by volume growth in its base business (insoluble sulphur) and operating leverage benefits arising out of brownfield nature of capacity expansion (11,000 tonne- two phases)
- Net sales in Q3FY19 came in at ₹ 94.5 crore, up 9.6%YoY. EBITDA in Q3FY19 was at ₹ 34.5 crore with corresponding EBITDA margins at 36.5%. Reported margins look unusually high as it includes forex gains, adjusted for same, the normalised margins stood at ~33%.
- Consequent PAT for Q3FY19 came in at ₹ 20.7 crore, up 35.3% YoY
- In the past, OCCL has successfully commissioned Phase 2 of expansion (5500 tonne) and is progressing well to reach peak utilisation in FY20E, thereby triggering the next level of capex in the similar business domain (insoluble sulphur)
- Currently, OCCL is also executing a buyback plan wherein the company intends to spend ~₹ 35 crore on buyback of shares from open market at a price not exceeding ₹ 1150/share. It intends to buy ~3.04 lakh shares (~3% of share capital). As on date (February 1), it has already completed ~57% of intended buyback (1.74 lakh shares)

#### Insoluble sulphur volumes to grow at ~11% CAGR in FY18-20E

OCCL is a speciality chemical company manufacturing insoluble sulphur, a critical vulcanisation agent for manufacturing tyres. It has successfully commissioned the Phase 2 of expansion (5500 tonne) in July 2018 and is progressing well to attain double digit volume growth in FY18-20E. With present installed capacity of 34,000 tonne; OCCL is well poised to clock insoluble sulphur sales volume of ~32,000 tonne in FY20E vs. ~26,000 tonne in FY18; implying a volume CAGR of ~11%. Sales volume in FY19E is expected at ~30,000 tonne. Initially for the last year, the company was scouting for opportunities for growth beyond FY20E in similar or different business profiles. However, the management commentary suggests an expansion in the insoluble sulphur segment with next leg of growth to be of similar magnitude i.e. ~11,000 tonne in two phases. We believe this will provide sustainable growth prospects given it is a critical raw material for manufacturing tyres, which has no threat of obsolesce due to upcoming electric/unmanned vehicle technology.

#### Low asset turns to limit expansion in return ratios, steady play, HOLD!

OCCL manufactures insoluble sulphur and is one of the three credible players worldwide. It operates in a closely guarded technology space with small industry size (~₹ 3500 crore) and low asset turnovers (~1x). This limit the competition in the marketplace. Therefore, given the impressive utilisation of the expanded capacity, the next leg of capex is on the anvil for OCCL. However, with low asset turns (~1x) and B2B nature of business profile, we expect limited scope RoCE expansion from the current levels, which will limit the valuation multiple expansion, going forward. From a fundamental perspective OCCL remains a steady business model wherein asset turnover is  $\sim 1x$ , EBITDA margins is  $\sim 30\%$ and net working capital cycle is ~75 days with consequent RoCE at ~20%. Going forward, over FY18-20E, expect sales, PAT to grow at a CAGR of 12.3%, 19.7%, respectively, wherein we build in 230 bps expansion in EBITDA margins to 32.2% in FY20E. We value OCCL at ₹ 1300 i.e. 16x P/E on FY20E EPS of ₹ 81.2/share and assign a HOLD rating to the stock. We draw comfort from healthy cash flow generation at OCCL with present CFO yield at ~8%. We also build in successful closure of buyback amounting to ~₹ 35 crore in FY19E.




## **Company Analysis**

OCCL is a JP Goenka Group company manufacturing insoluble sulphur under the brand "Diamond Sulf". The company was established in 1978 while it commenced manufacturing insoluble sulphur in 1994 with an installed capacity of 3,000 TPA. The company has a current capacity to manufacture 23,000 tonne of insoluble sulphur annually. It has two plants in India viz. Dharuhera, Haryana (12,000 tonne capacity) and Mundra SEZ, Gujarat (11,000 tonne capacity). In 2015, OCCL further commenced a brownfield expansion of 11,000 TPA at the existing Mundra facility of which both phases (of 5500 tonne each) have been successfully commissioned. The capex is estimated to cost  $\sim ₹$  159 crore with expected project IRR of  $\sim 20\%$  + and payback period of about four years.

#### Capacity expansion in place; impressive ramp-up bodes well!

Capacity utilisations levels peaked in FY16 with utilisations levels at ~90%. Sensing the constraints, the company executed a brownfield expansion with Phase 1 commissioned by end of FY17 and Phase 2 in Q2FY19. With robust demand, we expect a quick ramp up of capacities with capacity utilisation inching to ~95% in FY20E vs. ~91% in FY18.




Source: Company, ICICI Direct Research

We expect insoluble sulphur sales volume to grow at a CAGR of  ${\sim}11\%$  to  ${\sim}32$  KT by FY20E.

#### Net sales to be robust; tracking capacity expansion

With incremental capacities in place and steady realisations, we expect healthy volume led growth to led to 12.3% CAGR in sales in FY18-20E.



Source: Company, ICICI Direct Research

The new capacity is expected to be absorbed quickly as OCCL has a strong relationship with its customers amid healthy product demand


This is largely volume led growth with pricing expected to be stable amid stabilising crude oil prices and OCCL possessing a good bargaining power by virtue of it being a player in the oligopolistic market

Sales volumes are tilted more in the favour of exports vs. domestic. Exports share in total sales volume mix remains largely in the range of 65-70%



#### Healthy EBITDA & PAT growth, going forward

EBITDA is expected to grow at a CAGR of 16.5% in FY18-20E to ₹ 133.3 crore in FY20E. This is largely a result of sales volume growth (~11% CAGR) coupled with 230 bps expansion in EBITDA margins. EBITDA margins are expected to expand as the capex is brownfield in nature. This may result in sharing of overhead costs on expanded base.




Source: Company, ICICI Direct Research

Source: Company, ICICI Direct Research

In FY18-20E, on account of sales volume growth (12.3% CAGR), expansion in EBITDA margins (230 bps) and decline in interest costs (due to repayment of debt), we expect PAT to grow at a CAGR of 19.7% over FY18-20E to ₹ 81.3 core in FY20E. Corresponding EPS is expected at ₹ 72.0 in FY19E & ₹ 81.2 in FY20E.

#### Increasing profitability to result in improved return ratio profile

Post the blip in FY17, return ratios are expected to improve with RoE & RoCE expected to perk up to ~17% & ~22%, respectively, by FY20E. Return ratios are also suppressed due to surplus cash with the company, which it intends to spend on future growth opportunities for growth beyond FY20E.



#### Low planned capex, healthy cash flows improve debt gearing!


OCCL has a healthy balance sheet with gross debt of ₹ 112 crore as of FY18 with consequent debt: equity at 0.3x. We expect the debt gearing to be controlled due to healthy generation of cash from operations. OCCL is expected to generate average CFO of ~₹ 95 crore/year in FY18-20E with debt: equity expected to reduce further to  $\sim 0.2x$  in the aforesaid period. The company has also a controlled working capital cycle with net working capital days of ~73 days in FY18.



## **Outlook and valuation**

Oriental Carbon & Chemicals (OCCL) is a speciality chemical company manufacturing insoluble sulphur, a critical vulcanisation agent for manufacturing tyres. With limited competition and a unique product profile, OCCL has a strong presence in the domestic (~50% market share) as well as export markets. With the robust auto sector outlook, increasing share of radialisation in India's CV segment and operational efficiencies, OCCL is on a strong footing with robust prospects, going forward.

OCCL manufactures insoluble sulphur and is one of the three credible players worldwide. It operates in a closely guarded technology space with small industry size (~₹ 3500 crore) and low asset turnovers (~1x) which limit the competition in the market place. Therefore, given the impressive utilisation of the expanded capacity, the next leg of capex is on the anvil for OCCL. However, with low asset turns (~1x) and B2B nature of business profile we expect limited scope RoCE expansion from current levels, which will limit the valuation multiple expansion, going forward. From a fundamental perspective, OCCL remains a steady business model wherein asset turnover is  $\sim 1x$ , EBITDA margins is  $\sim 30\%$  and net working capital cycle is ~75 days with consequent RoCE at ~20%. It can certainly be held in one's portfolio from a long term investment horizon perspective. Going forward, over FY18-20E, expect sales, PAT to grow at a CAGR of 12.3% & 19.7%, respectively, wherein we build in 230 bps expansion in EBITDA margins to 32.2% in FY20E. We value OCCL at ₹ 1300 i.e. 16x P/E on FY20E EPS of ₹ 81.2/share with a HOLD rating on the stock. We draw comfort from healthy cash flow generation with present CFO yield at ~8%. We also build in successful closure of buyback amounting to ~₹ 35 crore in FY19E.



Source: Reuters, ICICI Direct Research





Source: Bloomberg, Company, ICICI Direct Research; \*I-direct coverage on Phillips Carbon Black was initiated on July 2016

Key events	
Date/Year	Event
2004	OCCL sets up second line of insoluble sulphur increasing its capacity in Dharuera by 4000 metric tonne (MT)
2010	The company increases insoluble sulphur capacity to 12000 MT through debottlenecking
2011	OCCL reports net sales of ₹ 158.2 cr (up 25.9% YoY) and net profit of ₹ 37.4 cr (up 27.2% YoY) on the back of robust global demand and capacity expansion through debottlenecking. Major tyre manufacturers identify OCCL as a strategic supplier
2012	The company commissions Phase I at the Mundra SEZ Plant (5500 MT) in August 2011 taking the total capacity to 17500 MT. Robust demand and product validation and approvals by major tyre manufacturers augurs well for the company thereby fastracking the capacity utilisation levels at OCCL
2013	OCCL fully commissions Phase II at the Mundra SEZ Plant (5500 MT) in May 2012 taking the total insoluble sulphur capacity to 23000 MT. OCCL was impacted by the global slowdown of insoluble sulphur demand as tyre companies took production cuts. OCCL acquires 50% stake in Schrader Duncan Ltd
2014	Domestic sales of insoluble sulphur grow 12% while export sales grow 14%. With existing land availability at Mundra facility and tyre industry steadily getting out or recession OCCL plans another expansion of 11000 MT over two phases
2015	In FY15, OCCL's gross revenue from insoluble sulphur increased 5% YoY. Export sales quantity increases 10% YoY on account of increased off take by existing customers and addition of some new customers. The growth rate in domestic volumes is only 6% as the tyre industry in India is in the grip of a slowdown and demand picks up late in the second half of the year
2016	OCCL executing brownfield expansion (11000 tonne in two phases with each phase of 5500 tonne) in Mundra. The first phase of capacity expansion is expected to be commissioned ahead of schedule by the end of FY17E against the initial guidance of April 2017
2017	OCCL successfully commissions Phase 1 (5500 tonne) facility in December 2017 at Mundra. The company expects to fully ramp up the facility within a year. OCCL is confident of tying up additional quantities in American and Chinese market, where it has begun to establish its presence
2018	OCCL has commenced trail runs from Phase 2 (5500 tonne) of brownfield expansion and expects it to commission soon. For full year FY18, Net sales stood at ₹ 328.2 crore (up 10.3% YoY), EBITDA stood at ₹ 98.2 crore (EBITDA margins at 29.9%, up 60 bps YoY) and PAT at ₹ 56.8 crore, up 6.4% YoY.

Source: Company, ICICI Direct Research

Top 1	Top 10 Shareholders				Sharehold	ling Patt	ern				
Rank	Name	Latest Filing Date	% 0/S	Position (m)	Change (m)	(in %)	Dec-17	Mar-18	Jun-18	Sep-18	Dec-18
1	Cosmopolitan Investments, Ltd.	30-Sep-18	19	1.9	0.0	Promoter	49.8	49.8	49.8	50.0	50.7
2	New India Investment Corporation, Ltd.	30-Sep-18	12	1.2	0.0	FII	1.2	1.4	1.0	0.4	0.4
3	Duncan International (India) Ltd.	30-Sep-18	10	1.0	0.0	DII	21.0	21.1	21.2	22.6	23.6
4	HDFC Asset Management Co., Ltd.	30-Sep-18	9	0.9	0.0	Others	28.0	27.8	28.0	26.9	25.3
5	L&T Investment Management Limited	30-Sep-18	7	0.7	0.1						
6	Haldia Investment Co., Ltd.	30-Sep-18	6	0.6	0.0						
7	Life Insurance Corporation of India	30-Sep-18	4	0.4	0.0						
8	General Insurance Corporation of India	30-Sep-18	3	0.3	0.0						
9	Goenka (Aparna)	30-Sep-18	2	0.2	0.0						
10	DSP Investment Managers Pvt. Ltd.	30-Sep-18	1	0.1	0.0						
Source	e: Reuters, ICICI Direct Research										
Rece	Recent Activity										
	Buys						Sells				

Duys				00113	
Investor name	Value (US\$M)	Shares(M)	Investor name	Value (US\$M)	Shares(M)
L&T Investment Management Limited	2.0	0.1			
HSBC Global Asset Management (India) Pvt Ltd	0.8	0.0			

Source: Reuters, ICICI Direct Research



# Financial summary (Standalone)

Profit and loss statement			₹ C	rore
(Year-end March)	FY17	FY18	FY19E	FY20E
Net Sales	294.5	328.2	381.7	414.0
Other Operating Income	3.0	0.0	0.0	0.0
Total Operating Income	297.5	328.2	381.7	414.0
Growth (%)	8.3	10.3	16.3	8.4
Raw Material Expenses	70.7	76.1	94.9	102.3
Employee Expenses	38.2	39.4	45.1	48.9
Power & Fuel Expenses	36.1	39.4	43.9	47.6
Other Operating Expense	65.1	75.2	75.4	82.0
Total Operating Expenditure	210.2	230.0	259.4	280.7
EBITDA	87.3	98.2	122.4	133.3
Growth (%)	7.7	12.6	24.6	8.9
Depreciation	15.2	16.3	18.8	20.3
Interest	5.1	7.9	8.2	6.4
Other Income	6.6	5.5	5.6	7.0
PBT	73.6	79.6	100.9	113.7
Exceptional Item	0.0	0.0	0.0	0.0
Total Tax	20.2	22.8	28.9	32.4
PAT	53.4	56.8	72.1	81.3
Growth (%)	0.9	6.2	27.0	12.8
EPS (₹)	51.8	55.1	72.0	81.2

Cash flow statement				₹ Crore
(Year-end March)	FY17	FY18	FY19E	FY20E
Profit after Tax	53.4	56.8	72.1	81.3
Add: Depreciation	15.2	16.3	18.8	20.3
(Inc)/dec in Current Assets	9.7	12.4	-19.3	-12.8
Inc/(dec) in CL and Provisions	12.2	2.8	11.2	5.3
Others	5.1	7.9	8.2	6.4
CF from operating activities	95.6	96.1	91.0	100.4
(Inc)/dec in Investments	-14.6	-22.7	0.0	-25.0
(Inc)/dec in Fixed Assets	-101.3	-56.2	-25.0	-10.0
Others	8.5	-17.4	0.0	0.0
CF from investing activities	-107.4	-96.3	-25.0	-35.0
Issue/(Buy back) of Equity	0.0	0.0	-0.3	0.0
Inc/(dec) in loan funds	24.1	15.5	-5.0	-35.0
Dividend paid & dividend tax	-12.4	-12.4	-14.4	-16.8
Inc/(dec) in Share Cap	0.0	0.0	0.0	0.0
Others	3.6	-0.8	-42.9	-6.4
CF from financing activities	15.3	2.4	-62.6	-58.2
Net Cash flow	3.5	2.3	3.4	7.3
Opening Cash	9.9	13.4	15.6	19.0
Closing Cash	13.4	15.6	19.0	26.3

Source: Company, ICICI Direct Research

Source: Company, ICICI Direct Research

Balance sheet			₹ Crore		
(Year-end March)	FY17	FY18	FY19E	FY20E	
Liabilities					
Equity Capital	10.3	10.3	10.0	10.0	
Reserve and Surplus	326.0	377.5	400.5	465.0	
Total Shareholders funds	336.3	387.8	410.5	475.0	
Total Debt	96.5	112.0	107.0	72.0	
Deferred Tax Liability & Others	29.6	20.6	20.6	20.6	
Total Liabilities	462.4	520.4	538.1	567.6	
Assets					
Gross Block	421.3	439.6	502.4	512.4	
Less: Acc Depreciation	115.2	131.6	150.4	170.7	
Net Block	306.1	308.0	352.0	341.7	
Capital WIP	2.4	40.4	2.5	2.5	
Total Fixed Assets	308.5	348.4	354.5	344.2	
Liquid Investments	30.1	52.8	52.8	77.8	
Other Investments	14.7	23.0	23.0	23.0	
Inventory	32.2	38.6	47.1	51.0	
Debtors	72.6	75.6	88.9	96.4	
Loans and Advances	34.3	17.8	15.3	16.6	
Other Current Assets	6.0	0.7	0.8	0.8	
Cash	13.4	15.6	19.0	26.3	
Total Current Assets	158.4	148.3	171.0	191.2	
Creditors	46.9	49.0	57.5	62.4	
Provisions	2.4	3.1	5.8	6.2	
Current Liabilities & Prov	49.3	52.1	63.3	68.6	
Net Current Assets	109.1	96.2	107.8	122.5	
Application of Funds	462.4	520.4	538.1	567.6	

Source: Company, ICICI Direct Research

Key ratios				
(Year-end March)	FY17	FY18	FY19E	FY20E
Per share data (₹)				
EPS	51.8	55.1	72.0	81.2
Cash EPS	66.5	70.9	90.8	101.5
BV	326.2	376.2	410.3	474.7
DPS	10.0	10.0	12.0	14.0
Cash Per Share (Incl Invst)	42.1	66.4	71.8	104.1
Operating Ratios (%)				
EBITDA Margin	29.3	29.9	32.1	32.2
PBT / Total Op. income	24.7	24.2	26.4	27.5
PAT Margin	18.0	17.3	18.9	19.6
Inventory days	39.9	42.9	45.0	45.0
Debtor days	89.9	84.1	85.0	85.0
Creditor days	58.1	54.5	55.0	55.0
Return Ratios (%)				
RoE	15.9	14.6	17.6	17.1
RoCE	15.3	15.5	19.0	22.4
RoIC	17.3	19.9	22.3	24.5
Valuation Ratios (x)				
P/E	23.2	21.8	16.7	14.8
EV / EBITDA	14.8	13.0	10.4	9.0
EV / Net Sales	4.4	3.9	3.3	2.9
Market Cap / Sales	4.2	3.8	3.2	3.0
Price to Book Value	3.7	3.2	2.9	2.5
Solvency Ratios				
Debt/EBITDA	1.1	1.1	0.9	0.5
Debt / Equity	0.3	0.3	0.3	0.2
Current Ratio	2.9	2.5	2.4	2.4
Quick Ratio	2.3	1.8	1.7	1.7
Source: Company ICICI Direct B	esearch			

Source: Company, ICICI Direct Research



### RATING RATIONALE

ICICIdirect endeavours to provide objective opinions and recommendations. ICICI direct Research assigns ratings to its stocks according to their notional target price vs. current market price and then categorises them as Strong Buy, Buy, Hold and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock.

Strong Buy: >15%/20% for large caps/midcaps, respectively, with high conviction; Buy: >10%/15% for large caps/midcaps, respectively; Hold: Up to +/-10%; Sell: -10% or more;



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, 1st Floor, Akruti Trade Centre, Road No 7, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com



### ANALYST CERTIFICATION

We /l Chirag Shah PGDBM; Shashank Kanodia CFA MBA (Capital Markets), Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

#### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. ICICI Securities Limited is a Sebi registered Research Analyst with Sebi Registration Number – INH00000990. ICICI Securities Limited Sebi Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities of any companies that the analysts cover.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction. ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.